Tenofovir (all routes except local)

Neonatal disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5304
R13750		 Jourdain a, 2018 Neonatal adverse event of grade 3 or 4 or serious adverse event (< 1 year) 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB 1.17 [0.71;1.94] C 43/161   38/160 81 161
ref
S5282
R13646		 Chi, 2007 Neonatal serious adverse event (within 2 weeks pp). late pregnancy randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF/emtracitabine Indication: HIV 0.86 [0.46;1.62] C 20/198   23/199 43 198
ref
Total 2 studies 1.04 [0.70;1.54] 124 359
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Jourdain a, 2018Jourdain a, 2018 1.17[0.71; 1.94]8116161%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Chi, 2007Chi, 2007 0.86[0.46; 1.62]4319839%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.04[0.70; 1.54]1243590.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0 RCTRCT 1.04[0.70; 1.54]1243590%NAJourdain a, 2018 Chi, 2007 2 Type of controls unexposed, sickunexposed, sick 1.04[0.70; 1.54]1243590%NAJourdain a, 2018 Chi, 2007 2 Tags Adjustment   - Randomisation  - Randomisation 1.04[0.70; 1.54]1243590%NAJourdain a, 2018 Chi, 2007 2 Control group   - Unexposed, sick  - Unexposed, sick 1.04[0.70; 1.54]1243590%NAJourdain a, 2018 Chi, 2007 2 Exposed group   - TDF (only)  - TDF (only) 1.17[0.71; 1.94]81161 -NAJourdain a, 2018 1   - TDF/emtracitabine  - TDF/emtracitabine 0.86[0.46; 1.62]43198 -NAChi, 2007 1 Indication   - CHB  - CHB 1.17[0.71; 1.94]81161 -NAJourdain a, 2018 1   - HIV  - HIV 0.86[0.46; 1.62]43198 -NAChi, 2007 1 All studiesAll studies 1.04[0.70; 1.54]1243590%NAJourdain a, 2018 Chi, 2007 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.04[0.70; 1.54]1243590%NAJourdain a, 2018 Chi, 2007 20.510.01.0